-
1.发明公开公开(公告)号：US20240033359A1
公开(公告)日：2024-02-01
申请号：US18256578
申请日：2021-12-09
Inventor： Gary SHAPIRO , Xingyue HE , Mei Rosa NG , Lorraine THOMPSON , Elena DE JUAN FRANCO , Steven VANCE
IPC: A61K39/00 , C12N5/0783 , C12N15/86 , C07K16/40 , C07K14/725 , A61P35/00
CPC classification number: A61K39/464454 , C12N5/0636 , C12N15/86 , C07K16/40 , A61K39/4611 , A61K39/4631 , C07K14/7051 , A61P35/00 , C12N2740/10043 , C12N2501/2302 , C07K2317/569 , C07K2317/92 , C07K2319/03
Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.
-
2.发明公开公开(公告)号：US20240050473A1
公开(公告)日：2024-02-15
申请号：US18256565
申请日：2021-12-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Gary SHAPIRO , Johara CHOUITAR , Xingyue HE , Mei Rosa NG
CPC classification number: A61K35/17 , C07K16/40 , A61K39/4611 , A61K39/4631 , A61K39/464454 , A61P35/00 , C12Y406/01002 , A61K2239/13 , A61K2239/21 , A61K2239/22 , A61K2239/17
Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) and chimeric antigen receptors comprising GCC antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules are provided herein.
-
公开(公告)号：US20240226295A9
公开(公告)日：2024-07-11
申请号：US18546384
申请日：2022-02-15
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Chantal KUHN , Gary SHAPIRO
CPC classification number: A61K39/4631 , A61K35/17 , A61P35/00 , A61P37/02 , C12N5/0636 , C12N15/63 , A61K2239/11 , A61K2239/21 , A61K2239/22 , C12N2510/00
Abstract: Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.
-
公开(公告)号：US20240131158A1
公开(公告)日：2024-04-25
申请号：US18546384
申请日：2022-02-15
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Chantal KUHN , Gary SHAPIRO
CPC classification number: A61K39/4631 , A61K35/17 , A61P35/00 , A61P37/02 , C12N5/0636 , C12N15/63 , A61K2239/11 , A61K2239/21 , A61K2239/22 , C12N2510/00
Abstract: Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.
-
-
-
Search Results
4
records
(took 0.022 seconds)
